This product is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate cancer (mHSPC), including patients who have not received endocrine therapy or have received endocrine therapy for no more than 3 months.
This product is combined with dexamethasone for adult patients with multiple myeloma who have received at least one therapy.
This product is indicated for the treatment of advanced epithelial ovarian cancer: •First-line therapy; •Second-line therapy following failure of other treatments. This product is also indicated for the treatment of small cell lung cancer and squamous cell carcinoma of the head and neck.
This product is indicated for the treatment of: -Adult patients and pediatric patients aged 2 years and older with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. -Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase or accelerated phase who are resistant or intolerant to prior therapies (including imatinib), as well as pediatric patients aged 2 years and older with Ph+ CML in the chronic phase.
For the treatment of: -Newly diagnosed glioblastoma multiforme, initially in combination with radiotherapy, followed by maintenance treatment. -Recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma after conventional treatment.
This product is indicated for the treatment of advanced epithelial ovarian cancer: •First-line therapy; •Second-line therapy following failure of other treatments. This product is also indicated for the treatment of small cell lung cancer and squamous cell carcinoma of the head and neck.
